IGF-1 LR3

IGF-1 long arginine 3 (IGF-1 LR3) is a peptide derivative of human insulin-like growth factor 1 (IGF-1; Item No. 33981) containing 13 additional amino acids at the N-terminus of IGF-1 as well as an arginine in place of glutamate at position 3 of IGF-1, a substitution that increases its half-life by reducing its interaction with IGF binding proteins (IGFBPs).¹ It stimulates protein and DNA synthesis (EC₅₀s = 0.19 and 1.8 nM, respectively) and prevents protein degradation in vitro (EC₅₀ = 0.53 nM) to a greater degree than IGF-1. IGF-1 LR3 (278 µg/animal per day) increases body weight, muscle RNA content, and muscle protein synthesis in a rat model of diabetes.² It reduces vessel stenosis and the necrotic core size of atherosclerotic plaques in a model of early atherosclerosis using ApoE^-/- mice.³

WARNING This product is not for human or veterinary use.

1. Francis, G.L., Ross, M., Ballard, F.J., et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J. Mol. Endocrinol. 8(3), 213-223 (1992).

2. Tomas, F.M., Knowles, S.E., Owens, P.C., et al. Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects. Biochem. J. 291(Pt 3), 781-786 (1993).

3. von der Thüsen, J.H., Borensztajn, K.S., Moimas, S., et al. IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. Am. J. Pathol. 178(2), 924-934 (2011).